Epizyme Phase 2 data at ASCO ‘looks solid’: Jefferies

Epizyme’s tazemetostat still looks ‘approvable and attractive,’ says Jefferies. After abstracts were released ahead of the ASCO meeting for new and updated Phase II tazemetostat data in mesothelioma and “more importantly” follicular lymphoma data to be presented at the EHA meeting, Jefferies analyst Michael Yee said the new lymphoma abstract data “looks solid.” The high responses rates support Yee’s view that tazemetostat looks like “an approval and attractive cancer drug,” he tells investors. Yee keeps a Buy rating on Epizyme with a $27 price target.

https://bit.ly/2Kv7QgP